Plain-English translation of NCT04427449 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called 4SCAR-CD44v6 T cell therapy, which uses your own immune cells that have been genetically modified in a laboratory to recognize and attack cancer cells. The modified cells are infused back into your body through an IV to fight cancers including stomach, breast, prostate, lymphoma, and multiple myeloma. Researchers want to see if this treatment is safe, feasible, and effective.
Many common cancers have a protein called CD44v6 on their surface that makes them good targets for immune therapy. This medication takes advantage of that target, offering a potentially new option for patients with cancers that haven't responded well to other treatments.
You likely qualify if…
You likely don't qualify if…
Your T cells (a type of immune cell) will be collected through a process similar to donating blood. These cells will be sent to a laboratory where they're genetically modified to recognize cancer cells, then grown in larger numbers. Once ready, the modified cells will be infused back into your body through an IV. You'll then be monitored closely to see how you respond and whether the treatment is working.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~100 participants
Started
June 2026
Primary completion
December 2029
Age range
6 Months – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.